度普利尤单抗治疗嗜酸性肉芽肿性多血管炎难治性慢性鼻窦炎
这项前瞻性观察研究纳入9例血管炎长期缓解但慢性鼻窦炎伴鼻息肉仍活动的嗜酸性肉芽肿性多血管炎患者,评估度普利尤单抗的疗效与安全性。治疗3个月55.6%达完全缓解,12个月升至83.3%,鼻部症状与患者报告结局显著改善,44.4%发生不良事件。
要点
- 9例EGPA合并难治性CRSwNP患者接受度普利尤单抗治疗。
- 完全缓解率3个月为55.6%,12个月为83.3%。
- 不良事件发生率44.4%,2例高嗜酸性粒细胞增多导致停药。
核心结论
- 度普利尤单抗是EGPA严重难治性耳鼻喉表现的有效治疗选择,可改善症状、减轻炎症并提高生活质量。
- 作者认为需仔细筛选患者并监测,以尽量减少不良事件并优化结局。
研究设计与样本
- 前瞻性观察研究,纳入2021年至2023年间接受度普利尤单抗治疗的EGPA患者。
- 纳入标准为血管炎表现长期缓解但仍有活动性CRSwNP的患者。
- 共纳入9例EGPA患者,进行临床、生物学及鼻科评估,并采集患者报告结局指标与鼻细胞学。
主要发现
- 治疗3个月后55.6%达完全缓解,12个月时升至83.3%。
- 鼻部症状及患者报告结局显著改善,疗效维持12个月。
- 生活质量改善,AAV-PRO评分显著降低。
- 鼻细胞学显示嗜酸性粒细胞和中性粒细胞计数减少。
- 不良事件发生率44.4%,其中2例高嗜酸性粒细胞增多导致度普利尤单抗停药。
关键数值与推荐
- 完全缓解定义为BVAS=0且泼尼松剂量≤4 mg/天。
- 部分缓解定义为BVAS=0且泼尼松剂量>4 mg/天。
临床怎么用
- 作者认为度普利尤单抗是EGPA严重难治性耳鼻喉表现的有效治疗选择。
- 作者认为需仔细筛选患者并监测,以尽量减少不良事件并优化结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Eosinophilic granulomatosis with polyangiitis (EGPA) is frequently associated with refractory chronic rhinosinusitis with nasal polyps (CRSwNP), despite current treatments. Dupilumab demonstrated efficacy in the treatment of severe and uncontrolled CRSwNP, with improvements in patient-reported outcome measures (PROMs) and in objective measurements. This study aims to evaluate efficacy and safety of dupilumab in refractory CRSwNP in EGPA patients. METHODS: A prospective observational study was conducted on EGPA patients treated with dupilumab between 2021 and 2023. Patients in a phase of prolonged remission of vasculitis manifestations but still experiencing active CRSwNP were included. Clinical, biological, and rhinologic evaluations were performed, alongside with PROMs and nasal cytology. Complete response was defined by BVAS = 0 and prednisone dose ≤4 mg/day, while partial response by BVAS = 0 and prednisone dose >4 mg/day. RESULTS: Nine EGPA patients were included. After 3 months, 55.6% achieved complete response, increasing to 83.3% at 12 months. Nasal symptoms and patient-reported outcomes improved significantly, with sustained efficacy over 12 months. An improvement in quality of life was also observed, with a significant reduction in the AAV-PRO score. Nasal cytology revealed reductions in eosinophils and neutrophils counts. Adverse events occurred in 44.4%, including hypereosinophilia in two cases, which led to dupilumab discontinuation. CONCLUSION: Dupilumab is an effective treatment option for severe and refractory ENT manifestations in EGPA, as it improves symptoms, reduces inflammation, and leads to better a quality of life. However, careful patient selection and monitoring are necessary to minimize adverse events and optimize outcomes.
引用
- Padoan R, Davanzo F, Iorio L, et al. Dupilumab for refractory chronic rhinosinusitis in eosinophilic granulomatosis with polyangiitis. Rheumatology (Oxford). 2025. PMID: 39412652. doi:10.1093/rheumatology/keae554
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。